aTyr Pharma, Inc.

As of June 30, 2026, aTyr Pharma, Inc. carries a market capitalization of 51.20M, placing it among publicly traded companies globally. Its enterprise value stands at 10.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

aTyr Pharma, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, aTyr Pharma, Inc. has 98.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 307.03, and the price-to-book ratio stands at 1.20.

These figures are as of June 30, 2026. The EV/Sales ratio of 64.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.66M versus a market cap of 51.20M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, aTyr Pharma, Inc. maintains a current ratio of 5.12, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, aTyr Pharma, Inc. posted a negative return on equity (ROE) of -98.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -70.97, reflecting losses generated across the asset base. The company generates approximately 2,855.06 in revenue per employee across its workforce of 58.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, aTyr Pharma, Inc.'s stock has declined approximately 81.72% over the past 52 weeks. The 50-day moving average sits at 0.33, while the 200-day moving average is 0.53.

Over the twelve months ended June 30, 2026, aTyr Pharma, Inc. generated 166,307.00 in revenue and converted that into -53.22M in net income, yielding earnings per share of -0.54. EBITDA reached -54.51M, while operating income came in at -55.89M.

As of June 30, 2026, aTyr Pharma, Inc. holds 50.26M in cash and equivalents against 9.89M in total debt, resulting in a net debt position of -14.14M. Total book value stands at 42.70M, with working capital of 41.11M providing operational flexibility.

aTyr Pharma, Inc. produced -47.74M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -244,208.70 in capital expenditures, free cash flow totaled -47.98M - equivalent to -0.49 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -33,609.47 and net profit margin of -32,003.68 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -93.97: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -49.94, meaning aTyr Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

aTyr Pharma, Inc.'s most recent stock split took place on July 1, 2019 with a 14:1 split ratio.

As of June 30, 2026, aTyr Pharma, Inc. has an Altman Z-Score of -13.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.